Methotrexat Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, stopping the conversion of folic acid to its active form. This limits the synthesis of thymidine and purines, essential building blocks for DNA and RNA, thereby reducing the growth of rapidly dividing cells and modulating immune responses.

The dose of Methotrexat Accord is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment goals. No fixed dosing information is provided here; the prescriber sets the appropriate regimen.

Methotrexat Accord is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because of a high risk of fetal malformations and loss. It is also not recommended while breastfeeding, as methotrexate can be excreted in milk and affect the infant.

To request Methotrexat Accord, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methotrexat Accord is a folate antagonist, similar in class to drugs like pemetrexed and leflunomide. Compared with newer agents, methotrexate has a long‑established efficacy profile, a broad range of indications, and a well‑characterized safety record, though monitoring requirements may be more intensive.

Methotrexat Accord should be stored at room temperature, preferably below 25 °C, in its original packaging. The container should be kept closed, protected from moisture and direct light, and stored away from sources of heat to maintain product stability.

Methotrexat Accord is supplied as a sterile injectable solution and is administered by a qualified healthcare professional via intra‑arterial, intramuscular or intrathecal injection, depending on the therapeutic indication and clinical protocol.

The most serious adverse risks include bone‑marrow suppression leading to severe anemia or infection, hepatotoxicity that can progress to fibrosis or cirrhosis, pulmonary toxicity such as pneumonitis, and renal failure. Patients should be monitored regularly for blood counts, liver and kidney function.

Methotrexat Accord should be avoided in pregnant or breastfeeding women, patients with severe renal or hepatic impairment, those with known hypersensitivity to methotrexate, and individuals receiving live vaccines. Clinicians must also assess for contraindications related to concurrent medications.